NKTX - Nkarta Inc

2.57
-0.010   -0.389%

Share volume: 751,151
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$2.58
-0.01
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 35%
Dept financing 23%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.80%
1 Month
28.50%
3 Months
37.43%
6 Months
24.15%
1 Year
43.58%
2 Year
-81.64%
Key data
Stock price
$2.57
P/E Ratio 
0.00
DAY RANGE
$2.53 - $2.68
EPS 
-$1.35
52 WEEK RANGE
$1.31 - $2.81
52 WEEK CHANGE
$41.21
MARKET CAP 
147.021 M
YIELD 
N/A
SHARES OUTSTANDING 
71.030 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
1.55
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$776,362
AVERAGE 30 VOLUME 
$718,647
Company detail
CEO: Paul J. Hastings
Region: US
Website: nkartatx.com
Employees: 140
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens.

Recent news